ARMD diagnostic device


Age-related macular degeneration is a debilitating disorder which affects up to 25% of those between the ages of 65 and 70. The condition is a leading cause of blindness in the UK and currently radical surgical intervention or expensive therapeutic treatment is required to delay the progression of the disease. To increase the chances of success with these treatments, early diagnosis is essential. Diagnosis and monitoring of disease progression is currently expensive and time consuming which leads to delays in treatment and poor prognosis.

The technology

This technology utilises a technique which analyses the earliest, sub-clinical changes within the eye and provides an opportunity to screen for ARMD allowing lifestyle changes to be recommended and emerging pharmaceuticals to be implemented. These interventions will act to delay disease progression, and hence this technology will act to slow the disease preserving quality of life for longer and delaying the onset of blindness.


This device will primarily be used by ophthalmologists to complement structural information obtained by existing diagnostic pathways. This will allow the effect of intervention to be monitored and disease progression to be more effectively monitored.

Key benefits

The key benefit of this technology is the speed and accuracy of the diagnosis. This device will allow for sub-clinical diagnosis of ARMD leading to an improved prognosis.


Expressions of interested from potential licensees or co-developers would be welcomed.

Intellectual property

Granted European and Chinese patents, pending in US, India and Japan.


Dr Leanne Burgin, Team Leader – IP Development and Partnering, UMIP, Tel: +44 (0) 161 306 8514